Longboard Pharmaceuticals, Inc.
https://www.longboardpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Longboard Pharmaceuticals, Inc.
Financial Market At The Start Of An Upswing, For Companies With Focused Strategies
Investors, advisors and companies that have raised cash recently insist funding is available and IPOs are possible for drug developers that can clearly outline future clinical milestones.
Finance Watch: J.P. Morgan Conference To Offer Glimpse Of 2024 Funding Forecast
Public Company Edition: Discussions at the J.P. Morgan Healthcare Conference 8-11 January in San Francisco should offer some insight on industry’s and investors’ expectations about the financial markets in 2024. The year started with some big financings, but also some new job cuts.
Longboard Surfs PACIFIC Waves To Pivotal Phase III Epilepsy Program
The company’s valuation quadrupled after it announced positive Phase Ib/IIa results for bexicaserin in Dravet syndrome, Lennox-Gastaut syndrome and other epileptic disorders.
Finance Watch: Biopharma IPOs Regain Momentum With Slate Of New Offerings
Public Company Edition: Instil Bio, Connect Biopharma, Finch Therapeutics, Gain Therapeutics and four heath care-focused SPACs launched initial public offerings; Endo raised $1.3bn via note sale; and Rubius Therapeutics, Solid Biosciences and others priced follow-on offerings.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice